中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2015年
9期
41-42
,共2页
神经生长因子%骨折%愈合
神經生長因子%骨摺%愈閤
신경생장인자%골절%유합
nerve growth factor%fracture%healing
目的：观察经皮局部注射神经生长因子对骨折愈合的影响。方法选取2014年1月至9月住院的84例骨折患者，根据随机数字表法将其分为对照组（口服三七片）和观察组（经皮局部注射神经生长因子），各42例，观察和比较两组临床疗效、骨折愈合时间、骨痂生长情况及不良反应发生情况。结果与对照组相比，观察组治愈率(50.00%比26.19%)及总有效率(97.62%比83.33%)明显升高（P＜0.05），胫骨干骨折愈合时间[(10.0±1.5）周比（12.5±2.4)周]、肱骨干骨折愈合时间[(7.2±1.1）周比（8.4±1.5)周]、股骨干骨折愈合时间[(11.0±2.5）周比（13.5±3.0)周]均明显缩短（P＜0.05）；术后3周内，两组骨痂最大直径[(4.5±1.1）mm比（4.4±1.1）mm ]比较，差异无统计学意义（ P＞0.05)；而术后3周以后，观察组骨痂最大直径较对照组明显增大[（7.2±1.8）mm比（5.5±1.3）mm ]（ P＜0.05）。两组均未出现严重不良反应。结论局部注射神经生长因子能够促进骨折愈合，且不良反应少，具有较高安全性，值得临床推广。
目的：觀察經皮跼部註射神經生長因子對骨摺愈閤的影響。方法選取2014年1月至9月住院的84例骨摺患者，根據隨機數字錶法將其分為對照組（口服三七片）和觀察組（經皮跼部註射神經生長因子），各42例，觀察和比較兩組臨床療效、骨摺愈閤時間、骨痂生長情況及不良反應髮生情況。結果與對照組相比，觀察組治愈率(50.00%比26.19%)及總有效率(97.62%比83.33%)明顯升高（P＜0.05），脛骨榦骨摺愈閤時間[(10.0±1.5）週比（12.5±2.4)週]、肱骨榦骨摺愈閤時間[(7.2±1.1）週比（8.4±1.5)週]、股骨榦骨摺愈閤時間[(11.0±2.5）週比（13.5±3.0)週]均明顯縮短（P＜0.05）；術後3週內，兩組骨痂最大直徑[(4.5±1.1）mm比（4.4±1.1）mm ]比較，差異無統計學意義（ P＞0.05)；而術後3週以後，觀察組骨痂最大直徑較對照組明顯增大[（7.2±1.8）mm比（5.5±1.3）mm ]（ P＜0.05）。兩組均未齣現嚴重不良反應。結論跼部註射神經生長因子能夠促進骨摺愈閤，且不良反應少，具有較高安全性，值得臨床推廣。
목적：관찰경피국부주사신경생장인자대골절유합적영향。방법선취2014년1월지9월주원적84례골절환자，근거수궤수자표법장기분위대조조（구복삼칠편）화관찰조（경피국부주사신경생장인자），각42례，관찰화비교량조림상료효、골절유합시간、골가생장정황급불량반응발생정황。결과여대조조상비，관찰조치유솔(50.00%비26.19%)급총유효솔(97.62%비83.33%)명현승고（P＜0.05），경골간골절유합시간[(10.0±1.5）주비（12.5±2.4)주]、굉골간골절유합시간[(7.2±1.1）주비（8.4±1.5)주]、고골간골절유합시간[(11.0±2.5）주비（13.5±3.0)주]균명현축단（P＜0.05）；술후3주내，량조골가최대직경[(4.5±1.1）mm비（4.4±1.1）mm ]비교，차이무통계학의의（ P＞0.05)；이술후3주이후，관찰조골가최대직경교대조조명현증대[（7.2±1.8）mm비（5.5±1.3）mm ]（ P＜0.05）。량조균미출현엄중불량반응。결론국부주사신경생장인자능구촉진골절유합，차불량반응소，구유교고안전성，치득림상추엄。
Objective To investigate the effect of percutaneous local injection of nerve growth factor ( NGF ) on fracture healing. Methods 84 fracture patients in our hospital from January 2014 to September 2014 were randomized into the control group ( oral Sanqi Tablets ) and the observation group ( percutaneous local injection of NGF ) according to the random number method, 42 cases in each group. The clinical efficacy, fracture healing time, bone callus growth state and adverse reactions were observed and compared in the two groups. Results Compared with the control group, the cure rate and total effective rate in the observation group were significantly increased ( 50. 00% vs. 26. 19%, 97. 62% vs. 83. 33%, P < 0. 05 ); compared with the control group, the fracture healing times of tibial shaft, humeral shaft and femoral shaft in the observation group were obviously reduced ( 10. 0 ± 1. 5 vs. 12. 5 ± 2. 4, 7. 2 ± 1. 1 vs. 8. 4 ± 1. 5, 11. 0 ± 2. 5 vs. 13. 5 ± 3. 0, P < 0. 05 );the maximum diameter of bone callus within 3 weeks after operation in the two groups had no statistical difference ( 4. 5 ± 1. 1 vs. 4. 4 ± 1. 1, P > 0. 05 ) , however, compared with the control group, the maximum diameter of bone callus at postoperative 3 weeks in the observation group was significantly increased ( 7. 2 ± 1. 8 vs. 5. 5 ± 1. 3, P < 0. 05 ) . No serious adverse reactions appeared during the treatment period in the two groups. Conclusion The percutaneous local injection of NGF can significantly promote the fracture healing and has less adverse reactions with high treatment security, and is worthy of clinical promotion.
